© 1988 by Oxford University Press
Journal of the National Cancer Institute, Vol. 80, No. 1, 21-29,
March 2, 1988
© 1988 Oxford University Press
Postoperative Adjuvant Chemotherapy or Radiation Therapy for Rectal Cancer: Results From NSABP Protocol R-0112
3University of Pittsburgh Pittsburgh, PA
*NSABP Headquarters, 3550 Terrace St., Room 914, Pittsburgh, PA 15261.
Information is presented from 555 patients with Dukes B and C rectal cancers treated by curative resection who were entered into the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol R-01 between November 1977 and October 1986. Their average time on study was 64.1 months. The patients were randomized to receive no further treatment (184 patients), postoperative adjuvant chemotherapy with 5-fluorouracil, semustine, and vincristine (MOF) (187 patients), or postoperative radiation therapy (184 patients). The chemotherapy group, when compared with the group treated by surgery alone, demonstrated an overall improvement in disease-free survival (P = .006) and in survival (P = .05). Employing the proportional hazards model, a global test was used to determine the presence of treatment interactions. Investigation of stratification variables employed in this study indicated that sex, and to a lesser extent age and Dukes stage, made individual contributions to the disease-free survival and the survival benefit from chemotherapy. When evaluated according to sex, the benefit for chemotherapy at 5 years, both in disease-free survival (29% vs. 47%; P < .001; relative odds, 2.00) and in survival (37% vs. 60%; P = .001; relative odds, 1.93), was restricted to males. When males were tested for age trend with the use of a logistic regression analysis, chemotherapy was found to be more advantageous in younger patients. When the group receiving postoperative radiation (4,600–4,700 rad in 26–27 fractions; 5, 100–5, 300 rad maximum at the perineum) was compared to the group treated only by surgery, there was an overall reduction in local-regional recurrence from 25% to 16% (P = .06). No significant benefit in overall disease-free survival (P = .4) or survival (P =.7) from the use of radiation has been demonstrated. The global test for interaction to identify heterogeneity of response to radiation within subsets of patients was not significant. In conclusion, this investigation has demonstrated a benefit from adjuvant chemotherapy (MOF) for the management of rectal cancer. The observed advantage was restricted to males. Postoperative radiation therapy reduced the incidence of local-regional recurrence, but it failed to affect overall disease-free survival and survival. [J Natl Cancer Inst 1988; 80: 21–29]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. T. Castaldo, A. A. Parikh, C. W. Pinson, I. D. Feurer, and N. B. Merchant Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer Arch Surg, February 1, 2009; 144(2): 129 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Kachnic, T. S. Hong, and D. P. Ryan Rectal Cancer at the Crossroads: The Dilemma of Clinically Staged T3, N0, M0 Disease J. Clin. Oncol., January 20, 2008; 26(3): 350 - 351. [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Willett, B. G. Czito, and J. C. Bendell Radiation Therapy in Stage II and III Rectal Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6903s - 6908s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Haddock, J. A. Sloan, J. W. Bollinger, G. Soori, P. D. Steen, and J. A. Martenson Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial J. Clin. Oncol., April 1, 2007; 25(10): 1255 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-P Machiels, C Sempoux, P Scalliet, J-C Coche, Y Humblet, E Van Cutsem, J Kerger, J-L Canon, M Peeters, S Aydin, et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann. Onc., April 1, 2007; 18(4): 738 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gill, A. W. Blackstock, and R. M. Goldberg Colorectal Cancer Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nissan, A. Stojadinovic, J. Shia, A. Hoos, J. G. Guillem, D. Klimstra, A. M. Cohen, B. D. Minsky, P. B. Paty, and W. D. Wong Predictors of Recurrence in Patients With T2 and Early T3, N0 Adenocarcinoma of the Rectum Treated by Surgery Alone J. Clin. Oncol., September 1, 2006; 24(25): 4078 - 4084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takiuchi Adjuvant Therapy in Rectal Cancer: What is the Truth? Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 191 - 192. [Full Text] [PDF]
|
|
|
|
|
|
A. De Paoli, S. Chiara, G. Luppi, M. L. Friso, G. D. Beretta, S. Del Prete, L. Pasetto, M. Santantonio, E. Sarti, G. Mantello, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study Ann. Onc., February 1, 2006; 17(2): 246 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. C. Gatter, A. L. Harris, and for Tumour and Angiogenesis Research Group Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8653 - 8660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Machiels, L. Duck, B. Honhon, B. Coster, J.-C. Coche, P. Scalliet, Y. Humblet, S. Aydin, J. Kerger, V. Remouchamps, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study Ann. Onc., December 1, 2005; 16(12): 1898 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Kidd, J. Yu, X. Li, W. D. Shannon, M. A. Watson, and H. L. McLeod Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2612 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sadahiro, T. Suzuki, K. Ishikawa, T. Nakamura, Y. Tanaka, K. Ishizu, S. Yasuda, H. Makuuchi, and C. Murayama Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 18 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Gunderson, D. J. Sargent, J. E. Tepper, N. Wolmark, M. J. O'Connell, M. Begovic, C. Allmer, L. Colangelo, S. R. Smalley, D. G. Haller, et al. Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer: A Pooled Analysis J. Clin. Oncol., May 15, 2004; 22(10): 1785 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Rice, D. J. Adelstein, M. A. Chidel, L. A. Rybicki, M. M. DeCamp, S. C. Murthy, and E. H. Blackstone Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1590 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Agulnik and M. R. Mullane Integrative Tumor Board: Colon Cancer with Liver Metastases Integr Cancer Ther, June 1, 2003; 2(2): 168 - 170. [PDF]
|
|
|
|
 |
|
 D. C. Hodgson, W. Zhang, A. M. Zaslavsky, C. S. Fuchs, W. E. Wright, and J. Z. Ayanian Relation of Hospital Volume to Colostomy Rates and Survival for Patients With Rectal Cancer J Natl Cancer Inst, May 21, 2003; 95(10): 708 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Dignam, Y. Ye, L. Colangelo, R. Smith, E. P. Mamounas, H. S. Wieand, and N. Wolmark Prognosis After Rectal Cancer in Blacks and Whites Participating in Adjuvant Therapy Randomized Trials J. Clin. Oncol., February 1, 2003; 21(3): 413 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Glimelius Radiotherapy in rectal cancer Br. Med. Bull., December 1, 2002; 64(1): 141 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy J. Clin. Oncol., April 1, 2002; 20(7): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Lee, J.-H. Lee, J.-H. Ahn, H. Bahng, T.-W. Kim, Y.-K. Kang, K.-H. Lee, J.-C. Kim, C.-S. Yu, J.-H. Kim, et al. Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report J. Clin. Oncol., April 1, 2002; 20(7): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A.M. Marijnen, E. Kapiteijn, C. J.H. van de Velde, H. Martijn, W. H. Steup, T. Wiggers, E. K. Kranenbarg, and J. W.H. Leer Acute Side Effects and Complications After Short-Term Preoperative Radiotherapy Combined With Total Mesorectal Excision in Primary Rectal Cancer: Report of a Multicenter Randomized Trial J. Clin. Oncol., February 1, 2002; 20(3): 817 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Glynne-Jones and J. Debus Improving Chemoradiotherapy in Rectal Cancer Oncologist, August 1, 2001; 6(2008): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hodgson, C. S. Fuchs, and J. Z. Ayanian Impact of Patient and Provider Characteristics on the Treatment and Outcomes of Colorectal Cancer J Natl Cancer Inst, April 4, 2001; 93(7): 501 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.A.M. Marijnen, I.D. Nagtegaal, E. K. Kranenbarg, J. Hermans, C.J.H. van de Velde, J.W.H. Leer, and J.H.J.M. van Krieken No Downstaging After Short-Term Preoperative Radiotherapy in Rectal Cancer Patients J. Clin. Oncol., April 1, 2001; 19(7): 1976 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Edler, M. Hallström, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer Clin. Cancer Res., April 1, 2000; 6(4): 1378 - 1384. [Abstract] [Full Text]
|
|
|
|
|
|
D. G. Haller Defining the Optimal Therapy for Rectal Cancer J Natl Cancer Inst, March 1, 2000; 92(5): 361 - 362. [Full Text] [PDF]
|
|
|
|
|
|
N. Wolmark, H. S. Wieand, D. M. Hyams, L. Colangelo, N. V. Dimitrov, E. H. Romond, M. Wexler, D. Prager, A. B. Cruz Jr., P. H. Gordon, et al. Randomized Trial of Postoperative Adjuvant Chemotherapy With or Without Radiotherapy for Carcinoma of the Rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02 J Natl Cancer Inst, March 1, 2000; 92(5): 388 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Swedish Rectal Cancer Trial Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer N. Engl. J. Med., April 3, 1997; 336(14): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Shibata, M. A. Reale, P. Lavin, M. Silverman, E. R. Fearon, G. Steele, J. M. Jessup, M. Loda, and I. C. Summerhayes The DCC Protein and Prognosis in Colorectal Cancer N. Engl. J. Med., December 5, 1996; 335(23): 1727 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Lichter and T. S. Lawrence Recent Advances in Radiation Oncology N. Engl. J. Med., February 9, 1995; 332(6): 371 - 379. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Moertel Chemotherapy for Colorectal Cancer N. Engl. J. Med., April 21, 1994; 330(16): 1136 - 1142. [Full Text]
|
|
|
|
|
|
J. C. Bennett and The Board on Health Sciences Policy of the Institu Inclusion of Women in Clinical Trials -- Policies for Population Subgroups N. Engl. J. Med., July 22, 1993; 329(4): 288 - 292. [Full Text]
|
|
|
|
|
|
G. Marks, M. Mohiuddin, A. Eitan, L. Masoni, and J. Rakinic High-Dose Preoperative Radiation and Radical Sphincter-Preserving Surgery for Rectal Cancer Arch Surg, December 1, 1991; 126(12): 1534 - 1540. [Abstract] [PDF]
|
|
|
|
|
|
P. Twomey, M. Burchell, D. Strawn, and J. Guernsey Local Control in Rectal Cancer: A Clinical Review and Meta-Analysis Arch Surg, October 1, 1989; 124(10): 1174 - 1179. [Abstract] [PDF]
|
|